Systematic review and metaanalysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam

Clinical Infectious Diseases

Volumn 64, Issue 5, 2017, Pages 666-674

  Hammond, Drayton A ^a   Smith, Melanie N ^b   Li, Chenghui ^a   Hayes, Sarah M ^c   Lusardi, Katherine ^a   Bookstaver, P Brandon ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acute kidney injury; Nephrotoxicity; Piperacillin tazobactam; Vancomycin

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACUTE KIDNEY FAILURE; DISEASE ASSOCIATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; META ANALYSIS; MONOTHERAPY; NEPHROTOXICITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 85018180208     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw811     Document Type: Review

References (38)

1. Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol 2012; 35:349-55.
2. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med 2010; 38:S169-74.
3. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330-6.
4. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycininduced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68:1243-55.
5. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-14.
6. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57:734-44.
7. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial. Antimicrob Agents Chemother 2011; 55:5475-9.
8. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014; 34:670-6.
9. Davies SW, Efird JT, Guidry CA, et al. Top guns: The "Maverick" and "Goose" of empiric therapy. Surg Infect (Larchmt) 2016; 17:38-47.
10. Fodero KE, Horey AL, Krajewski MP, Ruh CA, Sellick JA Jr, Mergenhagen KA. Impact of an antimicrobial stewardship program on patient safety in veterans prescribed vancomycin. Clin Ther 2016; 38:494-502.
11. Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 2014; 34:662-9.
12. Hammond DA, Smith MN, Painter JT, Meena NK, Lusardi K. Concomitant vancomycin and piperacillin-tazobactam does not increase acute kidney injury in critically ill patients. Pharmacotherapy 2016; 36:463-71.
13. Kim T, Kandiah S, Patel M, et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res Notes 2015; 8:579.
14. Navalkele B, Pogue JM, Karino S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin/tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis 2016. doi:10.1093/cid/ciw709.
15. Sutton JD, Mynatt RP, Kaye KS, Murray KP, Rybak MJ, Pogue JM. Nephrotoxicity comparison of two commercially available generic vancomycin products. Antimicrob Agents Chemother 2015; 59:5470-4.
16. Gao S, Li J, Li Z. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized children with or without concomitant piperacillin-tazobactam. Fudan Univ J Med Sci 2015; 42:743-8.
17. Knoderer CA, Gritzman AL, Nichols KR, Wilson AC. Late-occurring vancomycin-associated acute kidney injury in children receiving prolonged therapy. Ann Pharmacother 2015; 49:1113-9.
18. Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 2014; 34:653-61.
19. Moenster RP, Linneman TW, Finnegan PM, Hand S, Thomas Z, McDonald JR. Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect 2014; 20:O384-9.
20. McQueen KE, Clark DW. Does combination therapy with vancomycin and piperacillin-tazobactam increase the risk of nephrotoxicity versus vancomycin alone in pediatric patients? J Pediatr Pharmacol Ther 2016; 21:332-8.
21. Peyko V, Smalley S, Cohen H. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract 2016. doi:10.1177/0897190016628960.
22. Karino S, Kaye KS, Navalkele B, et al. Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin-tazobactam: opportunities for antimicrobial stewardship. Antimicrob Agents Chemother 2016; 60:3743-50.
23. Lorenz MA, Moenster RP, Linneman TW. Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure. J Med Microbiol 2016; 65:195-9.
24. Study Quality Assessment Tools. Available at: www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools. Accessed 5 June 2016.
25. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 2011; 55:3278-83.
26. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2012; 2:124-38.
27. Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis 2016; 63:300-9.
28. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61-e111.
29. Nishino Y, Takemura S, Minamiyama Y, et al. Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat. Redox Rep 2002; 7:317-9.
30. Le Moyec L, Racine S, Le Toumelin P, et al. Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. Crit Care Med 2002; 6:124-5.
31. Pill MW, O'Neill CV, Chapman MM, Singh AK. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. Pharmacotherapy 1997; 17:166-9.
32. Mac K, Chavada R, Paull S, Howlin K, Wong J. Cefepime induced acute interstitial nephritis-a case report. BMC Nephrol 2015; 16:15.
33. Tune BM, Hsu CY. The renal mitochondrial toxicity of beta-lactam antibiotics: in vitro effects of cephaloglycin and imipenem. J Am Soc Nephrol 1990; 1:815-21.
34. Bagshaw SM, Bellomo R, Devarajan P, et al. Review article: acute kidney injury in critical illness. Can J Anaesth 2010; 57:985-98.
35. Ragab AR, Al-Mazroua MK, Al-Harony MA. Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children. Infect Dis Ther 2013; 2:37-46.
36. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44.
37. Navalkele B, Karino S, Pogue J, et al. Acute kidney injury in patients on concomitant vancomycin and piperacillin/tazobactam: are extended infusions to blame? Open Forum Infect Dis 2015; 2:128.
38. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-7.